Immunology
Kawasaki Disease
6
Pipeline Programs↗
4
Active Trials↗
3
Companies Involved↗
Kawasaki Disease is an early-stage landscape with 6 programs across 3 companies. The most active players are Argenx, Bayer, Tanabe Pharma Corporation. 3 therapies are approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical3
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Analysis
Trial Status
23
clinical trials
Completed14 · 61%
Unknown status3 · 13%
Withdrawn2 · 9%
Active, not recruiting2 · 9%
Not yet recruiting1 · 4%
Recruiting1 · 4%
Clinical Trials
Trial Activity
23 trials
Efficacy of Immunoglobulin Plus Prednisolone in Reducing Coronary Artery Lesion in Patients With Kawasaki Disease
Active, not recruiting·—·Phase 3·NCT04078568·3,208 enrolled
A Randomized, Double Blind, Placebo Controlled Study of Etanercept in Children With Kawasaki Disease
Completed·—·Phase 2·NCT00841789·205 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)